STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews : A Journal of Medical Science and Technology

SARS-CoV-2 B.1.617.2 (Delta), B.1.617.2.1 (Delta Plus) Variant and Vaccine Strategies

  1. Chandani Chandani Kamble
  2. Vikas Kamble
  3. Prakash Kamble

Abstract

In India and other countries throughout the world, the Delta (B.1.617.2) variety has major devastation. First spotted in October 2020, it has already spread to more than 100 nations, prompting WHO to declare it as a worldwide variant of concern (VOC). Sub-lineages of the original B.1.617 variant include Delta (B.1.617.2), Delta plus (B.1.617.2.1), and Kappa (B.1.617.1). Vaccine deployment, safe-distancing, and timely lockdowns significantly reduced COVID-19 hospitalizations and deaths before the implementation of B.1.617. The Delta variant, which is said to be more contagious and for which existing vaccines appear to be ineffective, has sparked a recurrence of cases. As a result, there is a pressing need for better B.1.617 variant surveillance. While the Delta variant is gradually outpacing the Beta variant in terms of distribution, the Beta variant spread remains a concern due to its vaccine resistance.

Keywords

Support